Albenatide vs Visepegenatide (PB-119)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline

Albenatide

Developed by ConjuChem and partners

Phase 3 in Type 2 Diabetespeptide
Partial signal

NCT07058545 · Phase 3 · completed

The study randomized 474 participants to CJC-1134-PC or placebo and blinded participants, care providers, investigators, and outcome assessors. Its primary endpoint was change in HbA1c at Week 25, a surrogate measure, and the registry does not report whether the comparison was favorable or statistically significant.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

No aligned efficacy figure on record for this race.

Visepegenatide (PB-119)

Marketed by PegBio

Phase 3 in Type 2 Diabetespeptide
Reliable signal

NCT04504396 · Phase 3 · completed

This randomized, placebo-controlled trial kept participants, care providers, investigators and outcome assessors blind to treatment assignment. Its primary endpoint, change in HbA1c, was clearly met, with PB-119 producing a significantly larger reduction than placebo (P<0.001).

Reported efficacy

Change in HbA1c (week 1, week 25): Change in HbA1c from baseline: -1.25% (95% CI -1.35 to -1.16) with visepegenatide (PB-119) vs -0.68% (95% CI -0.78 to -0.59) with placebo; treatment difference -0.57% (95% CI -0.71 to -0.43), p<0.001. (met)

Result source: NCT04504396

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAlbenatideVisepegenatide (PB-119)
HbA1c, change-0.8% vs -0.5%−0.4 vs placebo1.5 mg · wk 12.14 · n 44NCT00638716
1 other result
  • -1.3% vs -0.3% 1.5 mg · wk 12.14 · n 27 · Phase 2 · primary NCT00674466
-1.4% vs -0.6%a−0.7 vs placebowk 24NCT04504370
1 other result
Body weight, change (kg)-2.0 vs -1.6−0.4 vs placebo1.5 mg · wk 12.14 · n 44NCT00638716
1 other result
  • -1.2 vs -0.4 1.5 mg · wk 12.14 · n 27 · Phase 2 · secondary NCT00674466
—Not posted · NCT04504396
HbA1c below 7%—Not posted · NCT07058545—Not posted · NCT04504396
Fasting plasma glucose, change-0.8 vs -0.6−0.2 vs placebo1.5 mg · wk 12.14 · n 42NCT00638716
1 other result
  • -0.3 vs 0.7 1.5 mg · wk 12.14 · n 27 · Phase 2 · secondary NCT00674466
—Not posted · NCT04504396
3-point MACE (% with event)—Not posted · NCT07058545—Not posted · NCT04504396

HbA1c, change

Albenatide
-0.8% vs -0.5%−0.4 vs placebo1.5 mg · wk 12.14 · n 44NCT00638716
1 other result
  • -1.3% vs -0.3% 1.5 mg · wk 12.14 · n 27 · Phase 2 · primary NCT00674466
Visepegenatide (PB-119)
-1.4% vs -0.6%a−0.7 vs placebowk 24NCT04504370
1 other result

Body weight, change (kg)

Albenatide
-2.0 vs -1.6−0.4 vs placebo1.5 mg · wk 12.14 · n 44NCT00638716
1 other result
  • -1.2 vs -0.4 1.5 mg · wk 12.14 · n 27 · Phase 2 · secondary NCT00674466
Visepegenatide (PB-119)
—Not posted · NCT04504396

HbA1c below 7%

Albenatide
—Not posted · NCT07058545
Visepegenatide (PB-119)
—Not posted · NCT04504396

Fasting plasma glucose, change

Albenatide
-0.8 vs -0.6−0.2 vs placebo1.5 mg · wk 12.14 · n 42NCT00638716
1 other result
  • -0.3 vs 0.7 1.5 mg · wk 12.14 · n 27 · Phase 2 · secondary NCT00674466
Visepegenatide (PB-119)
—Not posted · NCT04504396

3-point MACE (% with event)

Albenatide
—Not posted · NCT07058545
Visepegenatide (PB-119)
—Not posted · NCT04504396
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Albenatide: 3 of 4 rows · Visepegenatide (PB-119): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAlbenatideVisepegenatide (PB-119)
Dropout rate
14%1.5 mga
NCT00638716 · Phase 2 · registry result, not featured evidence
show 1 more result
23.3%1.5 mg
NCT00674466 · Phase 2 · registry result, not featured evidence
—
Discontinued due to AEs
—1.5 mga
NCT00638716 · Phase 2 · registry result, not featured evidence
show 1 more result
—1.5 mg
NCT00674466 · Phase 2 · registry result, not featured evidence
—
Serious AEs
0%1.5 mga
NCT00638716 · Phase 2 · registry result, not featured evidence
show 1 more result
3.3%1.5 mg
NCT00674466 · Phase 2 · registry result, not featured evidence
—
Most frequent reported AEs
1.5 mga
nausea 22.4% (placebo 15.8%)
diarrhea 12.2% (placebo 5.3%)
vomiting 12.2% (placebo 3.5%)
NCT00638716 · Phase 2 · registry result, not featured evidence
show 1 more result
1.5 mg
headache 26.7% (placebo 24.1%)
nausea 26.7% (placebo 13.8%)
vomiting 23.3% (placebo 17.2%)
NCT00674466 · Phase 2 · registry result, not featured evidence
—

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Albenatide

Fasting Plasma Glucose -0.75 vs -0.56 placebo mmol/L @ 12.14wk1.5 mg
absolute change · mmol/L
NCT00638716 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -13.48 mg/dL as posted
show 1 more result
-0.33 vs 0.67 placebo mmol/L @ 12.14wk*1.5 mg
NCT00674466 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -5.88 mg/dL as posted
Weight -1.98 vs -1.58 placebo kg @ 12.14wk1.5 mg
absolute change · kg
NCT00638716 · Phase 2 · registry result, not featured evidence
show 1 more result
-1.17 vs -0.39 placebo kg @ 12.14wk1.5 mg
NCT00674466 · Phase 2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Albenatide's landscape · Visepegenatide (PB-119)'s landscape